Target family: Chemokine receptors (type: gpcr)
Target: CCR3

Ligand: AZD3778 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.199999809265137 pKi
Reference (Journal): The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Published in: Bioorg Med Chem Lett

Ligand: banyu (I) (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pKi
Reference (Journal): Identification of full, partial and inverse CC chemokine receptor 3 agonists using [35S]GTPgammaS binding.
Published in: Eur J Pharmacol

Ligand: BMS compound 87b (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pKi
Reference (Journal): CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.
Published in: Bioorg Med Chem Lett

Ligand: CCL11 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines.
Published in: J Clin Invest

Ligand: CCL11 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans.
Published in: Genes Immun

Ligand: CCL11 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.
Published in: J Biol Chem

Ligand: CCL11 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3.
Published in: J Biol Chem

Ligand: CCL11 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): A novel, selective, and orally available antagonist for CC chemokine receptor 3.
Published in: J Pharmacol Exp Ther

Ligand: CCL11 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
Published in: J Exp Med

Ligand: CCL11 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
Published in: J Exp Med

Ligand: CCL13 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): A novel, selective, and orally available antagonist for CC chemokine receptor 3.
Published in: J Pharmacol Exp Ther

Ligand: CCL13 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines.
Published in: J Clin Invest

Ligand: CCL15 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.6 pIC50
Reference (Journal): Characterisation of macrophage inflammatory protein-5/human CC cytokine-2, a member of the macrophage-inflammatory-protein family of chemokines.
Published in: Eur J Biochem

Ligand: CCL18 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): CCL18 exhibits a regulatory role through inhibition of receptor and glycosaminoglycan binding.
Published in: PLoS ONE

Ligand: CCL2 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
Published in: J Exp Med

Ligand: CCL24 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): A novel, selective, and orally available antagonist for CC chemokine receptor 3.
Published in: J Pharmacol Exp Ther

Ligand: CCL24 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): High level expression, activation, and antagonism of CC chemokine receptors CCR2 and CCR3 in Chinese hamster ovary cells.
Published in: Cytokine

Ligand: CCL26 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): High level expression, activation, and antagonism of CC chemokine receptors CCR2 and CCR3 in Chinese hamster ovary cells.
Published in: Cytokine

Ligand: CCL26 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): A novel, selective, and orally available antagonist for CC chemokine receptor 3.
Published in: J Pharmacol Exp Ther

Ligand: CCL26 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3.
Published in: J Biol Chem

Ligand: CCL28 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -

Ligand: CCL5 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
Published in: J Exp Med

Ligand: CCL7 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
Published in: J Exp Med

Ligand: CCL8 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  -

Ligand: CXCL10 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: CXCL11 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: CXCL9 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: GW766994 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Chemokine receptor antagonists.
Published in: J Med Chem

Ligand: HIV-Tat (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.2 pIC50
Reference (Journal): HIV-1 Tat protein mimicry of chemokines.
Published in: Proc Natl Acad Sci USA

Ligand: HIV-Tat (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: lazucirnon (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.489999771118164 pKi
Reference (Patent): Co-crystals and salts of ccr3-inhibitors

Ligand: Met-Ckβ7 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.2 pIC50
Reference (Journal): C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap.
Published in: J Immunol

Ligand: RO116-4875/608 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.2 pIC50
Reference (Journal): Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists.
Published in: Am J Respir Crit Care Med

Ligand: RO116-9132/238 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9 pIC50
Reference (Journal): Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists.
Published in: Am J Respir Crit Care Med

Ligand: RO320-2947/001 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.4 pIC50
Reference (Journal): Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists.
Published in: Am J Respir Crit Care Med

Ligand: RO330-0802/001 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.3 pIC50
Reference (Journal): Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists.
Published in: Am J Respir Crit Care Med

Ligand: SB328437 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pKi

Ligand: [125I]CCL11 (human) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.3 pKd
Reference (Journal): Identification of full, partial and inverse CC chemokine receptor 3 agonists using [35S]GTPgammaS binding.
Published in: Eur J Pharmacol

Ligand: [125I]CCL5 (human) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: [125I]CCL7 (human) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  -

Ligand: [3H]banyu (I) (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Median affinity: 8.3 pKd
Reference (Journal): Identification of full, partial and inverse CC chemokine receptor 3 agonists using [35S]GTPgammaS binding.
Published in: Eur J Pharmacol

Ligand: UCB35625 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.03000020980835 pIC50
Reference (Journal): A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.
Published in: J Biol Chem

Ligand: YM-355179 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): A novel, selective, and orally available antagonist for CC chemokine receptor 3.
Published in: J Pharmacol Exp Ther